What is Precirix?
Founded in 2014 as a spin-off from the VUB, Precirix operates at the intersection of biotechnology and precision medicine. The company specializes in the design and development of radiopharmaceuticals labeled with radioisotopes, utilizing camelid single-domain antibodies to achieve high-affinity targeting. This technological foundation enables a sophisticated theragnostic approach, allowing clinicians to select patients via low-dose imaging before administering therapeutic doses. With a robust pipeline that includes one candidate in clinical trials and two in advanced preclinical stages, Precirix is establishing itself as a key player in the European biopharmaceutical landscape, focusing on improving patient outcomes through targeted, isotope-based interventions.
How much funding has Precirix raised?
Precirix has raised a total of $117.8M across 2 funding rounds:
Series A
$29.8M
Series B
$88M
Series A (2018): $29.8M with participation from Fournier-Majoie Foundation
Series B (2022): $88M led by INKEF Capital, Forbion, and Jeito
Key Investors in Precirix
INKEF Capital
An Amsterdam-based venture capital firm founded by the Dutch pension fund ABP, focusing on long-term support for innovative companies in healthcare and technology.
Forbion
A global life sciences firm with a strong track record of guiding biotech companies from early-stage development through to clinical success.
Jeito
A Paris-based investment firm dedicated to accelerating medical innovation by providing significant capital and expert support to build market leaders in therapeutic areas.
What's next for Precirix?
With the recent infusion of capital, Precirix is poised to scale its clinical operations and solidify its market position in the competitive radiopharmaceutical sector. The strategic focus will likely center on the progression of its lead product candidate through clinical milestones while simultaneously advancing its preclinical assets. Furthermore, the company is expected to leverage its platform's versatility to explore new isotope applications and combination therapies, potentially broadening its therapeutic reach. As the firm matures, the integration of its theragnostic model into standard oncology care pathways will be a critical indicator of its long-term commercial viability and impact on patient survival rates.
See full Precirix company page
